US20210038821A1 - Injection Device - Google Patents
Injection Device Download PDFInfo
- Publication number
- US20210038821A1 US20210038821A1 US16/976,202 US201916976202A US2021038821A1 US 20210038821 A1 US20210038821 A1 US 20210038821A1 US 201916976202 A US201916976202 A US 201916976202A US 2021038821 A1 US2021038821 A1 US 2021038821A1
- Authority
- US
- United States
- Prior art keywords
- sleeve
- injection device
- detector
- clutch
- teeth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002347 injection Methods 0.000 title claims abstract description 57
- 239000007924 injection Substances 0.000 title claims abstract description 57
- 238000012545 processing Methods 0.000 claims abstract description 42
- 230000007246 mechanism Effects 0.000 claims abstract description 28
- 230000033001 locomotion Effects 0.000 claims abstract description 27
- 239000004020 conductor Substances 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 7
- 238000012937 correction Methods 0.000 claims description 5
- 230000001939 inductive effect Effects 0.000 claims description 5
- 239000007769 metal material Substances 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims 1
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 description 54
- 108010011459 Exenatide Proteins 0.000 description 50
- 229960001519 exenatide Drugs 0.000 description 50
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 22
- QEFRNWWLZKMPFJ-YGVKFDHGSA-N L-methionine S-oxide Chemical compound CS(=O)CC[C@H](N)C(O)=O QEFRNWWLZKMPFJ-YGVKFDHGSA-N 0.000 description 22
- 230000008878 coupling Effects 0.000 description 21
- 238000010168 coupling process Methods 0.000 description 21
- 238000005859 coupling reaction Methods 0.000 description 21
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 21
- 239000012634 fragment Substances 0.000 description 10
- 235000001014 amino acid Nutrition 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 9
- 238000012377 drug delivery Methods 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 8
- 239000000427 antigen Substances 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 238000004891 communication Methods 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 239000003055 low molecular weight heparin Substances 0.000 description 3
- 229940127215 low-molecular weight heparin Drugs 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 2
- 208000002249 Diabetes Complications Diseases 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- 108010088406 Glucagon-Like Peptides Proteins 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- LMHMJYMCGJNXRS-IOPUOMRJSA-N exendin-3 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@H](C)O)[C@H](C)O)C(C)C)C1=CC=CC=C1 LMHMJYMCGJNXRS-IOPUOMRJSA-N 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000001831 (C6-C10) heteroaryl group Chemical group 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010037003 Buserelin Proteins 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 1
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102400000932 Gonadoliberin-1 Human genes 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101500026183 Homo sapiens Gonadoliberin-1 Proteins 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- XVVOERDUTLJJHN-UHFFFAOYSA-N Lixisenatide Chemical compound C=1NC2=CC=CC=C2C=1CC(C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(N)=O)C(=O)NCC(=O)NCC(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N1C(CCC1)C(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)CC)NC(=O)C(NC(=O)C(CC(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCSC)NC(=O)C(CCC(N)=O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC=1C=CC=CC=1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)CNC(=O)C(N)CC=1NC=NC=1)C(C)O)C(C)O)C(C)C)CC1=CC=CC=C1 XVVOERDUTLJJHN-UHFFFAOYSA-N 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 108010021717 Nafarelin Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 108010010056 Terlipressin Proteins 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 108010050144 Triptorelin Pamoate Proteins 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229960002719 buserelin Drugs 0.000 description 1
- CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229960004281 desmopressin Drugs 0.000 description 1
- NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960005153 enoxaparin sodium Drugs 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 108010015174 exendin 3 Proteins 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960001442 gonadorelin Drugs 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 239000000960 hypophysis hormone Substances 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004026 insulin derivative Substances 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- XVVOERDUTLJJHN-IAEQDCLQSA-N lixisenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 XVVOERDUTLJJHN-IAEQDCLQSA-N 0.000 description 1
- 108010004367 lixisenatide Proteins 0.000 description 1
- 229960001093 lixisenatide Drugs 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- RWHUEXWOYVBUCI-ITQXDASVSA-N nafarelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 RWHUEXWOYVBUCI-ITQXDASVSA-N 0.000 description 1
- 229960002333 nafarelin Drugs 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000036316 preload Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229960004532 somatropin Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 241001223854 teleost fish Species 0.000 description 1
- 229960003813 terlipressin Drugs 0.000 description 1
- BENFXAYNYRLAIU-QSVFAHTRSA-N terlipressin Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CN)CSSC1 BENFXAYNYRLAIU-QSVFAHTRSA-N 0.000 description 1
- CIJQTPFWFXOSEO-NDMITSJXSA-J tetrasodium;(2r,3r,4s)-2-[(2r,3s,4r,5r,6s)-5-acetamido-6-[(1r,2r,3r,4r)-4-[(2r,3s,4r,5r,6r)-5-acetamido-6-[(4r,5r,6r)-2-carboxylato-4,5-dihydroxy-6-[[(1r,3r,4r,5r)-3-hydroxy-4-(sulfonatoamino)-6,8-dioxabicyclo[3.2.1]octan-2-yl]oxy]oxan-3-yl]oxy-2-(hydroxy Chemical compound [Na+].[Na+].[Na+].[Na+].O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1O)NC(C)=O)O[C@@H]1C(C[C@H]([C@@H]([C@H]1O)O)O[C@@H]1[C@@H](CO)O[C@H](OC2C(O[C@@H](OC3[C@@H]([C@@H](NS([O-])(=O)=O)[C@@H]4OC[C@H]3O4)O)[C@H](O)[C@H]2O)C([O-])=O)[C@H](NC(C)=O)[C@H]1C)C([O-])=O)[C@@H]1OC(C([O-])=O)=C[C@H](O)[C@H]1O CIJQTPFWFXOSEO-NDMITSJXSA-J 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 229960004824 triptorelin Drugs 0.000 description 1
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31533—Dosing mechanisms, i.e. setting a dose
- A61M5/31535—Means improving security or handling thereof, e.g. blocking means, means preventing insufficient dosing, means allowing correction of overset dose
- A61M5/31541—Means preventing setting of a dose beyond the amount remaining in the cartridge
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31525—Dosing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31533—Dosing mechanisms, i.e. setting a dose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31533—Dosing mechanisms, i.e. setting a dose
- A61M5/31545—Setting modes for dosing
- A61M5/31548—Mechanically operated dose setting member
- A61M5/3155—Mechanically operated dose setting member by rotational movement of dose setting member, e.g. during setting or filling of a syringe
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31533—Dosing mechanisms, i.e. setting a dose
- A61M5/31545—Setting modes for dosing
- A61M5/31548—Mechanically operated dose setting member
- A61M5/3155—Mechanically operated dose setting member by rotational movement of dose setting member, e.g. during setting or filling of a syringe
- A61M5/31551—Mechanically operated dose setting member by rotational movement of dose setting member, e.g. during setting or filling of a syringe including axial movement of dose setting member
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31533—Dosing mechanisms, i.e. setting a dose
- A61M5/31545—Setting modes for dosing
- A61M5/31548—Mechanically operated dose setting member
- A61M5/3155—Mechanically operated dose setting member by rotational movement of dose setting member, e.g. during setting or filling of a syringe
- A61M5/31553—Mechanically operated dose setting member by rotational movement of dose setting member, e.g. during setting or filling of a syringe without axial movement of dose setting member
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31533—Dosing mechanisms, i.e. setting a dose
- A61M5/31545—Setting modes for dosing
- A61M5/31548—Mechanically operated dose setting member
- A61M5/3156—Mechanically operated dose setting member using volume steps only adjustable in discrete intervals, i.e. individually distinct intervals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31565—Administration mechanisms, i.e. constructional features, modes of administering a dose
- A61M5/31576—Constructional features or modes of drive mechanisms for piston rods
- A61M5/31583—Constructional features or modes of drive mechanisms for piston rods based on rotational translation, i.e. movement of piston rod is caused by relative rotation between the user activated actuator and the piston rod
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M2005/3125—Details specific display means, e.g. to indicate dose setting
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M2005/3125—Details specific display means, e.g. to indicate dose setting
- A61M2005/3126—Specific display means related to dosing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/02—General characteristics of the apparatus characterised by a particular materials
- A61M2205/0227—Materials having sensing or indicating function, e.g. indicating a pressure increase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/02—General characteristics of the apparatus characterised by a particular materials
- A61M2205/0233—Conductive materials, e.g. antistatic coatings for spark prevention
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3317—Electromagnetic, inductive or dielectric measuring means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3365—Rotational speed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/50—General characteristics of the apparatus with microprocessors or computers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
- A61M2205/581—Means for facilitating use, e.g. by people with impaired vision by audible feedback
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31565—Administration mechanisms, i.e. constructional features, modes of administering a dose
- A61M5/3159—Dose expelling manners
- A61M5/31593—Multi-dose, i.e. individually set dose repeatedly administered from the same medicament reservoir
Definitions
- the present disclosure is generally directed to an injection device, i.e. a drug delivery device for selecting and dispensing a number of user-variable doses of a medicament.
- Pen type drug delivery devices have application where regular injection by persons without formal medical training occurs. This may be increasingly common among patients having diabetes where self-treatment enables such patients to conduct effective management of their disease.
- a drug delivery device allows a user to individually select and dispense a number of user-variable doses of a medicament.
- the present disclosure is not directed to so called fixed dose devices which only allow dispensing of a predefined dose without the possibility to increase or decrease the set dose.
- resettable devices i.e., reusable
- non-resettable i.e., disposable
- disposable pen delivery devices are supplied as self-contained devices.
- Such self-contained devices do not have removable pre-filled cartridges. Rather, the pre-filled cartridges may not be removed and replaced from these devices without destroying the device itself. Consequently, such disposable devices need not have a resettable dose setting mechanism.
- the present disclosure is applicable for both types of devices, i.e. for disposable devices as well as for reusable devices.
- a cartridge typically includes a reservoir that is filled with a medication (e.g., insulin), a movable rubber type bung or stopper located at one end of the cartridge reservoir, and a top having a pierceable rubber seal located at the other, often necked-down, end.
- a medication e.g., insulin
- a movable rubber type bung or stopper located at one end of the cartridge reservoir
- a top having a pierceable rubber seal located at the other, often necked-down, end.
- a crimped annular metal band is typically used to hold the rubber seal in place. While the cartridge housing may be typically made of plastic, cartridge reservoirs have historically been made of glass.
- the needle assembly is typically a replaceable double-ended needle assembly. Before an injection, a replaceable double-ended needle assembly is attached to one end of the cartridge assembly, a dose is set, and then the set dose is administered. Such removable needle assemblies may be threaded onto, or pushed (i.e., snapped) onto the pierceable seal end of the cartridge assembly.
- the dosing section or dose setting mechanism is typically the portion of the pen device that is used to set (select) a dose.
- a spindle or piston rod contained within the dose setting mechanism presses against the bung or stopper of the cartridge. This force causes the medication contained within the cartridge to be injected through an attached needle assembly. After an injection, as generally recommended by most drug delivery device and/or needle assembly manufacturers and suppliers, the needle assembly is removed and discarded.
- a further differentiation of drug delivery device types refers to the drive mechanism: There are devices which are manually driven, e.g. by a user applying a force to an injection button, devices which are driven by a spring or the like and devices which combine these two concepts, i.e. spring assisted devices which still require a user to exert an injection force.
- the spring-type devices involve springs which are preloaded and springs which are loaded by the user during dose selecting. Some stored-energy devices use a combination of spring preload and additional energy provided by the user, for example during dose setting.
- An injection device comprising a housing with a receptacle for the product, a dosing mechanism for setting a product dosage to be administered and for displaying the set product dosage and a dispensing mechanism for dispensing the product is known e.g. from EP 2 814 547 B1 which discloses a manually driven device or from WO 2014/117944 A1, WO 2016/016184 A1 or WO 2017/134131 A1 which disclose spring driven devices.
- the display of such devices typically involves a number sleeve with a series of numbers corresponding to dose sizes being provided on the outer surface of the number sleeve such that only the actually set dose is visible through an opening or window in the housing.
- An injection device comprises a housing with a receptacle for the product, a dosing mechanism for setting a product dosage to be administered and for displaying the set product dosage and a dispensing mechanism for dispensing the product.
- the dosing mechanism may comprise a dosing sleeve, e.g. a number sleeve with numbers or symbols provided on its outer surface, which is rotatable relative to the housing in a first direction for setting a product dosage and which is rotatable relative to the housing in a second, opposite direction for correcting or dispensing a product dosage.
- the dispensing mechanism of the device may comprise a piston rod, which is moveable relative to the housing in a dispensing direction in order to eject the set product dosage in a dispensing stroke corresponding to the set product dosage, at least one sleeve, which is rotatable together with the dosing sleeve relative to the housing in the second direction in order to eject the set product dosage, and a clutch interposed between the dosing sleeve and the at least one sleeve and rotatable with the dosing sleeve and/or the at least one sleeve.
- the present disclosure is based on the idea that detecting movements of one or more component parts of the injection device may be used to identify e.g.
- the device may further comprise at least a first detector for detecting movement of the clutch relative to the dosing sleeve and/or the housing and/or the at least one sleeve and a data processing unit connected to the first detector for reading, storing, processing, transmitting and/or displaying signals received from the first detector.
- the clutch may comprise first ratchet teeth for engaging corresponding first teeth of the dosing sleeve such that relative incremental rotation of the dosing sleeve with respect to the clutch in one direction, preferably the first direction, is permitted while prevented in the opposite direction and second ratchet teeth for engaging corresponding second teeth of the at least one sleeve such that relative incremental rotation of the clutch with respect to the at least one sleeve in one direction, preferably the second direction, is permitted while prevented in the opposite direction.
- the teeth may have the form of saw-teeth.
- the clutch may have the form of a toothed ring, like the toothed ring provided interposed between the dosing sleeve and the coupling sleeve in EP 2 814 547 B1.
- the first ratchet teeth and the second ratchet teeth are located on the clutch facing in opposite axial directions.
- the incremental or stepwise rotation may cause a clicking sound every time a pair of teeth re-engages thereby providing an acoustical and/or tactile feedback to the user.
- one click corresponds to one dose unit such that counting the number of clicks enables a user to identify the set dose size.
- the present disclosure is suitable for devices permitting dose setting and dispensing the set dose as well as devices permitting dose setting, dose correcting and dispensing the set dose.
- dose correcting is defined as reducing the size of a set dose without dispensing the set dose.
- dose setting is used indicating increasing the set dose
- dose correcting is used indicating decreasing the set dose.
- Dose setting and dose correcting may include relative movement of the first and/or second ratchet teeth. Thus, detecting the clicks produced during dose setting and during dose correcting may be used to identify the resulting dose size.
- the first detector and the data processing unit are preferably adapted to detect at least one of a rotational movement of the clutch, an angle of rotation the rotational movement of the stop wheel and a direction of the rotational movement of the stop wheel. Detecting start and stop of the rotational movement is indicative of the device being used or not. Further, the angle of rotation is indicative of the size of a dose which is selected and/or dispensed by the drug delivery device.
- the direction of the rotational movement is indicative of the operation mode of the device, for example if the clutch rotates in a first direction during dose setting and rotates in a second, opposite direction during dose correction and/or dose dispensing. Summarizing, detecting the movement of the clutch provides the required information for giving a feedback to the user regarding the operation mode of the device.
- the data processing unit may be adapted to provide information about the dose size and/or amount of product ejected from the device by the dispensing mechanism and/or the maximum dose set by the dosing mechanism based on a rotation protocol containing data received from the first detector.
- Either the first detector and/or a further detector are adapted to detect the relative incremental rotation between the clutch and any further component part of the device, e.g. the dosing sleeve and/or the housing and/or the at least one sleeve, in the first direction and/or in the second direction.
- the relative incremental rotation between the clutch and the dosing sleeve and/or the at least one sleeve may generate an acoustic feedback to a user.
- the first detector comprises at least one sensor for detecting this acoustic feedback generated by relative incremental rotation between the clutch and the dosing sleeve and/or the at least one sleeve.
- the sound generated during dose setting may differ from the sound generated during dose correcting such that the sensor may differentiate between dose setting and dose correcting.
- Other features may be used in conjunction or as an alternative to identify whether a dose is set or corrected, e.g. detecting the direction of rotation of the clutch and/or other component parts.
- the first ratchet teeth and/or the second ratchet teeth may be coated with a galvanic conductive material and at least one of the first teeth and/or at least one of the second teeth are provided with an elastic galvanic contact arranged for engaging with the galvanic conductive material at each rotational increment.
- the first detector comprises the elastic galvanic contact and the galvanic conductive material and each incremental rotational movement provides an electric signal which may be counted by the data processing unit.
- the resulting dose is e.g. calculated in counting the signals at the dialing end, e.g. the interface between the dose sleeve and the clutch, and subtracting the counted signals of the correcting end, e.g. the interface between the clutch and the at least one sleeve.
- the first detector comprises at least one mechanical switch which is provided between the first ratchet teeth and the first teeth and/or between the second ratchet teeth and the second teeth and is arranged for detecting engaging of the teeth at each rotational increment.
- Each switch engages with the respective ratchet teeth at each incremental rotation and thus produces an electrical signal.
- the dose calculation is done in a similar manner by the data processing unit as mentioned above.
- the first detector comprises at least one of a magnetic sensor and an inductive sensor, e.g. suitable to detect the rotational position of the dosing sleeve and/or the clutch.
- Data received from such a sensor may be analyzed by an add-on device attached e.g. to a button or to the dosing sleeve.
- This method may be used to calculate the set dose size taking into account a possible dose correction. In other words, it is possible to detect the chosen dose by analyzing the rotational positions of the dosing sleeve and the clutch.
- the injection device may further comprise a second detector for detecting the relative axial position of the clutch and the dosing sleeve.
- the data processing unit may be connected to the second detector for reading, storing, processing, transmitting and/or displaying signals received from the second detector.
- the additional detector may be required to differentiate between dose setting, dose correcting and/or dose dispensing be determining the relative axial position of the dosing sleeve relative to the clutch.
- the second detector comprises at least one of a magnetic sensor and an inductive sensor.
- Using a magnetic sensor or an inductive sensor may require that the clutch and/or the dosing sleeve comprise a metallic material.
- the dosing sleeve and/or the clutch may be metallized, coated, printed or additives may be added to the component parts, which typically mainly comprise a plastic material.
- the data processing unit may be adapted to provide information about the device being in its dose setting mode, its dose correction mode or its dose dispensing mode based on data received from the first detector and the second detector.
- the data processing unit may be provided within the housing of the injection device.
- the data processing unit and the first and second detector may be permanently provided within the housing of the injection device. This includes embodiments in which the data processing unit is connected to at least one of the first and second detector by wire.
- the data processing unit may be detachable from the housing and/or may be connected to at least one of the first and second detector by means of a wireless connection.
- the data processing unit may be an add-on device which may be attached to the housing and removed from the housing. Examples for wireless communication between the data processing unit and at least one detector may include communication via a near field communication (NFC) or via Bluetooth (BT).
- NFC near field communication
- BT Bluetooth
- the data processing unit may be adapted to send data to and/or receive data from a separate data processing and/or display device, e.g. portable handheld electronic devices, via a near field communication (NFC) or via Bluetooth (BT).
- the data may be queried after each use (injection) and read out or an add-on device could read, process and store the data and send a rotation protocol via to another device for further processing.
- the add-on device may alternatively transmit unprocessed data.
- the at least one sleeve may be a component part which is in direct engagement with the piston rod.
- the at least one sleeve may be a drive sleeve which is splined to the piston rod or which is in threaded engagement with the piston rod.
- the at least one sleeve may be a component part which is indirectly coupled to the piston rod, for example with a clutch or a transmission element interposed between the at least one sleeve and the piston rod.
- the at least one sleeve may be permanently coupled to the piston rod or may be selectively coupled to the piston rod only in a certain mode of the injection device, for example during dose dispensing.
- the injection device may comprise two sleeves, which are rotatable relative to the housing in order to eject the set product dosage and which are rotationally constrained relative to each other but displaceable relative to each other in the dispensing direction.
- the second detector may detect actuation, i.e. rotation, of one of these sleeves or of both sleeves.
- the injection device typically comprises a cartridge containing a medicament.
- medicament means a pharmaceutical formulation containing at least one pharmaceutically active compound,
- the pharmaceutically active compound has a molecular weight up to 1500 Da and/or is a peptide, a protein, a polysaccharide, a vaccine, a DNA, a RNA, an enzyme, an antibody or a fragment thereof, a hormone or an oligonucleotide, or a mixture of the above-mentioned pharmaceutically active compound,
- the pharmaceutically active compound is useful for the treatment and/or prophylaxis of diabetes mellitus or complications associated with diabetes mellitus such as diabetic retinopathy, thromboembolism disorders such as deep vein or pulmonary thromboembolism, acute coronary syndrome (ACS), angina, myocardial infarction, cancer, macular degeneration, inflammation, hay fever, atherosclerosis and/or rheumatoid arthritis,
- diabetes mellitus or complications associated with diabetes mellitus such as diabetic retinopathy, thromboembolism disorders such as deep vein or pulmonary thromboembolism, acute coronary syndrome (ACS), angina, myocardial infarction, cancer, macular degeneration, inflammation, hay fever, atherosclerosis and/or rheumatoid arthritis,
- diabetes mellitus or complications associated with diabetes mellitus such as diabetic retinopathy, thromboembolism disorders such as deep vein or pulmonary thromboembolism, acute coronary
- the pharmaceutically active compound comprises at least one peptide for the treatment and/or prophylaxis of diabetes mellitus or complications associated with diabetes mellitus such as diabetic retinopathy,
- the pharmaceutically active compound comprises at least one human insulin or a human insulin analogue or derivative, glucagon-like peptide (GLP-1) or an analogue or derivative thereof, or exendin-3 or exendin-4 or an analogue or derivative of exendin-3 or exendin-4.
- GLP-1 glucagon-like peptide
- exendin-3 or exendin-4 or an analogue or derivative of exendin-3 or exendin-4.
- Insulin analogues are for example Gly(A21), Arg(B31), Arg(B32) human insulin; Lys(B3), Glu(B29) human insulin; Lys(B28), Pro(B29) human insulin; Asp(B28) human insulin; human insulin, wherein proline in position B28 is replaced by Asp, Lys, Leu, Val or Ala and wherein in position B29 Lys may be replaced by Pro; Ala(B26) human insulin; Des(B28-B30) human insulin; Des(B27) human insulin and Des(B30) human insulin.
- Insulin derivates are for example B29-N-myristoyl-des(B30) human insulin; B29-N-palmitoyl-des(B30) human insulin; B29-N-myristoyl human insulin; B29-N-palmitoyl human insulin; B28-N-myristoyl LysB28ProB29 human insulin; B28-N-palmitoyl-LysB28ProB29 human insulin; B30-N-myristoyl-ThrB29LysB30 human insulin; B30-N-palmitoyl-ThrB29LysB30 human insulin; B29-N—(N-palmitoyl-Y-glutamyl)-des(B30) human insulin; B29-N—(N-lithocholyl-Y-glutamyl)-des(B30) human insulin; B29-N-( ⁇ -carboxyheptadecanoyl)-des(B30) human insulin and B29-N-( ⁇ -carboxy
- Exendin-4 for example means Exendin-4(1-39), a peptide of the sequence H-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2.
- Exendin-4 derivatives are for example selected from the following list of compounds:
- Hormones are for example hypophysis hormones or hypothalamus hormones or regulatory active peptides and their antagonists as listed in Rote Liste, ed. 2008, Chapter 50, such as Gonadotropine (Follitropin, Lutropin, Choriongonadotropin, Menotropin), Somatropine (Somatropin), Desmopressin, Terlipressin, Gonadorelin, Triptorelin, Leuprorelin, Buserelin, Nafarelin, Goserelin.
- Gonadotropine Follitropin, Lutropin, Choriongonadotropin, Menotropin
- Somatropine Somatropin
- Desmopressin Terlipressin
- Gonadorelin Triptorelin
- Leuprorelin Buserelin
- Nafarelin Goserelin.
- a polysaccharide is for example a glucosaminoglycane, a hyaluronic acid, a heparin, a low molecular weight heparin or an ultra low molecular weight heparin or a derivative thereof, or a sulphated, e.g. a poly-sulphated form of the above-mentioned polysaccharides, and/or a pharmaceutically acceptable salt thereof.
- An example of a pharmaceutically acceptable salt of a poly-sulphated low molecular weight heparin is enoxaparin sodium.
- Antibodies are globular plasma proteins ( ⁇ 150 kDa) that are also known as immunoglobulins which share a basic structure. As they have sugar chains added to amino acid residues, they are glycoproteins.
- the basic functional unit of each antibody is an immunoglobulin (Ig) monomer (containing only one Ig unit); secreted antibodies can also be dimeric with two Ig units as with IgA, tetrameric with four Ig units like teleost fish IgM, or pentameric with five Ig units, like mammalian IgM.
- Ig immunoglobulin
- the Ig monomer is a “Y”-shaped molecule that consists of four polypeptide chains; two identical heavy chains and two identical light chains connected by disulfide bonds between cysteine residues. Each heavy chain is about 440 amino acids long; each light chain is about 220 amino acids long. Heavy and light chains each contain intrachain disulfide bonds which stabilize their folding. Each chain is composed of structural domains called Ig domains. These domains contain about 70-110 amino acids and are classified into different categories (for example, variable or V, and constant or C) according to their size and function. They have a characteristic immunoglobulin fold in which two ⁇ sheets create a “sandwich” shape, held together by interactions between conserved cysteines and other charged amino acids.
- Ig heavy chain There are five types of mammalian Ig heavy chain denoted by ⁇ , ⁇ , ⁇ , ⁇ , and ⁇ .
- the type of heavy chain present defines the isotype of antibody; these chains are found in IgA, IgD, IgE, IgG, and IgM antibodies, respectively.
- Distinct heavy chains differ in size and composition; ⁇ and ⁇ contain approximately 450 amino acids and ⁇ approximately 500 amino acids, while ⁇ and ⁇ have approximately 550 amino acids.
- Each heavy chain has two regions, the constant region (CH) and the variable region (VH).
- the constant region is essentially identical in all antibodies of the same isotype, but differs in antibodies of different isotypes.
- Heavy chains ⁇ , ⁇ and ⁇ have a constant region composed of three tandem Ig domains, and a hinge region for added flexibility; heavy chains ⁇ and ⁇ have a constant region composed of four immunoglobulin domains.
- the variable region of the heavy chain differs in antibodies produced by different B cells, but is the same for all antibodies produced by a single B cell or B cell clone.
- the variable region of each heavy chain is approximately 110 amino acids long and is composed of a single Ig domain.
- a light chain has two successive domains: one constant domain (CL) and one variable domain (VL).
- CL constant domain
- VL variable domain
- the approximate length of a light chain is 211 to 217 amino acids.
- Each antibody contains two light chains that are always identical; only one type of light chain, ⁇ or ⁇ , is present per antibody in mammals.
- variable (V) regions are responsible for binding to the antigen, i.e. for its antigen specificity.
- VL variable light
- VH variable heavy chain
- CDRs Complementarity Determining Regions
- an “antibody fragment” contains at least one antigen binding fragment as defined above, and exhibits essentially the same function and specificity as the complete antibody of which the fragment is derived from.
- Limited proteolytic digestion with papain cleaves the Ig prototype into three fragments. Two identical amino terminal fragments, each containing one entire L chain and about half an H chain, are the antigen binding fragments (Fab).
- the Fc contains carbohydrates, complement-binding, and FcR-binding sites.
- F(ab′)2 is divalent for antigen binding.
- the disulfide bond of F(ab′)2 may be cleaved in order to obtain Fab′.
- the variable regions of the heavy and light chains can be fused together to form a single chain variable fragment (scFv).
- Pharmaceutically acceptable salts are for example acid addition salts and basic salts.
- Acid addition salts are e.g. HCl or HBr salts.
- Basic salts are e.g. salts having a cation selected from alkali or alkaline, e.g. Na+, or K+, or Ca2+, or an ammonium ion N+(R1)(R2)(R3)(R4), wherein R1 to R4 independently of each other mean: hydrogen, an optionally substituted C1-C6-alkyl group, an optionally substituted C2-C6-alkenyl group, an optionally substituted C6-C10-aryl group, or an optionally substituted C6-C10-heteroaryl group.
- solvates are for example hydrates.
- FIG. 1 shows an exploded view of the individual parts of an embodiment of an injection device according to the disclosure
- FIG. 2 shows a sectional view of a detail of the embodiment of FIG. 1 ;
- FIGS. 3 a -3 c show component parts of the injection device of FIG. 1 ;
- FIG. 4 schematically shows a data processing unit together with sensors.
- FIG. 1 shows an exploded view of the individual parts of an embodiment of an injection device according to the disclosure.
- This embodiment is designed as a so-called single-use pen. That is to say, the injection device is issued to the user fully assembled, i.e., with product to be administered.
- the typical course of the injection process may be as follows: the user removes the protective cap 1 from the injection device and mounts an injection needle (not shown) on the needle holder 2 a of a receptacle 2 . Now the dosage can be adjusted via the rotary knob 11 a .
- the rotary knob 11 a is turned so that the dosing sleeve 50 , which forms a dosing mechanism or is part of a dosing mechanism, is screwed out of the injection device.
- the dosing sleeve 50 is screwed out of the injection device until the desired dosage is displayed in the window of the threaded sleeve 9 . If an excessively high dosage is inadvertently set, the dosage can be corrected by turning the rotary knob in the opposite direction, whereby the dosing sleeve 50 is screwed back into the housing.
- the dosing device limits the maximum adjustable dosage to a predetermined value. If there is an attempt to screw the dosing sleeve out of the housing past this value, a radial limit stop on the dosing sleeve 50 and a counter-limit stop on the threaded sleeve 9 prevent further rotation by mutual interaction.
- the dosing sleeve 50 rotates relative to the coupling sleeve 40 .
- the coupling sleeve 40 is held rotationally fixedly in a form fit or friction fit against the housing 5 by a reverse rotation lock, for example by means of a toothed ring 7 a rotationally fixed to the threaded nut 7 and biased axially towards a corresponding set of ratchet teeth on an inner surface of the housing 5 by means of a spring 7 b .
- This ratchet between the housing 5 and the threaded nut 7 may form a clicker generating an audible and/or tactile feedback during dose dispensing as the teeth of ring 7 a slip over the corresponding teeth of housing 5 .
- the coupling sleeve 40 is permanently rotationally locked to the axially stationary threaded nut 7 by splines permitting relative axial movement between the coupling sleeve 40 which is axially entrained by the dosing sleeve 50 and the stationary threaded nut 7 .
- the threaded nut 7 may be retained in the housing 5 by means of an insert 6 holding the threaded nut 7 against the bias of spring 7 b .
- a clutch 60 is shown in FIG. 1 as a toothed ring which is interposed between rotary knob 11 a and a flange on coupling sleeve 40 such that relative rotation of the dosing sleeve 50 and the coupling sleeve 40 is permitted during dose setting.
- the clutch is provided with first ratchet teeth 61 on an end facing towards corresponding first teeth 51 of the dosing sleeve 50 and is provided with second ratchet teeth 62 on an opposite end facing towards corresponding second teeth 41 of the coupling sleeve 40 .
- the ratchet teeth interface 61 , 51 between the dosing sleeve 50 and the clutch 60 is designed such that rotation of the dosing sleeve 50 in a first direction, e.g. during dose setting, is permitted relative to the stationary clutch 60 with teeth 51 , 61 slipping over each other and re-engaging in rotational increments. Due to the saw-tooth like design of the teeth 51 , 61 relative rotation of the dosing sleeve 50 and the clutch 60 in the opposite direction is prevented.
- the ratchet teeth interface 62 , 41 between the coupling sleeve 40 and the clutch 60 is designed such that rotation of the clutch 60 in a second direction, e.g.
- multiple teeth 61 , 62 , 51 and 41 are shown.
- the function of the injection device would be the same if with the clutch 60 having multiple first ratchet teeth 61 at least one tooth 51 would be provided on the dosing sleeve 50 and vice versa.
- multiple second ratchet teeth 62 may interact with at least one tooth 41 and vice versa. While the torque transmitted by an interface having multiple engaging teeth may be increased compared with only a single pair of teeth engaging, providing only one or only few teeth on one of the component parts may have advantages when providing a sensor in or on this component part.
- the injection needle can be inserted at the intended position on the body of the user. Then the user pushes the ejection button 14 in the distal axial direction against the bias of spring 13 which is interposed between button 14 and coupling sleeve 40 .
- This axial movement blocks a relative rotation between the coupling sleeve 40 and the dosing sleeve 50 by means of the toothed ring of clutch 60 , i.e. the coupling sleeve 40 and the dosing sleeve 50 are rotationally constrained via the clutch 60 .
- the dosing sleeve begins to move back into the housing in a screwing motion.
- the coupling sleeve 40 carries out the same movement as the dosing sleeve 50 . Because the coupling sleeve 40 is permanently rotationally locked to the axially stationary threaded nut 7 , the rotational movement of the dosing sleeve 50 is transmitted to the threaded nut 7 . No axial forces are transmitted to the threaded nut 7 , because the coupling sleeve 40 is mounted axially movably on the threaded nut 7 .
- the rotating threaded nut 7 produces an axial movement of the threaded piston rod 8 in the distal direction, wherein the latter is guided axially and locked rotationally in the housing 5 by means of splines 8 a and is in threaded engagement with threaded nut 7 by means of an external thread 8 g .
- the flange 4 acts on the plug of the cartridge 3 and pushes it, corresponding to the displacement of the threaded piston rod 8 in the distal direction as well, wherein the previously set dosage can be ejected or administered.
- FIG. 1 shows an optional limiting device which ensures that the most recently set dosage can be completely ejected or injected.
- the dosing sleeve 50 has a coaxially applied inner toothing and the coupling sleeve 40 has a lateral cutout in which the stop wheel 30 is inserted.
- the function of the limiting device is described in EP 2 814 547 B1 in more detail.
- FIG. 1 further shows a data processing unit 20 connected to a first detector 21 and a second detector 22 for reading data responsive to signals received from the first and second detectors 21 , 22 .
- the data processing unit 20 is depicted as a component part being disposed on the outer surface of the housing 5 . It may be permanently attached to the housing 5 or may be an integral part thereof or may be a separate, detachable unit.
- the data processing unit 20 may comprise a power supply and a PCB suitable for e.g. data processing, data storing and/or display of information.
- the first detector 21 is disposed on the clutch 60 .
- the first detector 21 may comprise a coating on the ratchet teeth 61 , 62 of the clutch.
- the ratchet teeth 61 , 62 are coated with a galvanic conductive material and an, e.g. elastically deformable, galvanic contact is arranged on first teeth 51 and/or second teeth 41 to engage with the galvanic conductive material.
- an electric signal may be generated or transmitted.
- the first detector 21 may be provided on the dosing sleeve 50 .
- the first detector 21 may be a magnetic rotation encoder (quadrature), a vibrating structure microelectromechanical systems (MEMS) gyroscope or a combination of an MEMS gyroscope and an accelerometer. These small size devices may be easibily integrated into the dosing sleeve 50 .
- gyroscopes measure rotational motion.
- MEMS (microelectromechanical system) gyroscopes are small, inexpensive sensors that measure angular velocity. The units of angular velocity are measured in degrees per second (°/s) or revolutions per second (RPS). Hence, when determining the duration of the measurement the rotation angle can be determined that provides information about the dose size.
- the optional second detector 22 is disposed in or on the housing 5 at a position suitable for detecting axial movement of the clutch 60 .
- the second detector 22 may be arranged on the dosing sleeve 50 . If the first detector 21 is provided on the dosing sleeve 50 , the first and second detectors 21 , 22 may be integrated into a single detector unit.
- FIG. 4 shows the first detector 21 with two sensors 21 a and 21 b located on respective sides of clutch 60 and connected to the data processing unit 20 .
- the processing of the signals from the sensors in the data processing unit 20 is schematically indicated in FIG. 4 .
- a data processing unit 20 using the signals of a first detector 21 and, optionally, a second detector 22 for counting the size of the set dose may be applied to other drug delivery devices having a component part, like a sleeve, wheel or ring, performing a certain axial and/or rotational movement only during dose setting and a different movement during dose correcting.
- Examples for devices into which the data processing unit 20 with the first detector 21 and the second detector 22 may be implemented are disclosed in WO 2014/117944 A1, in WO 2016/016184 A1, in WO 2017/134131 A1 or in WO 2016/001304 A1.
- An injection device comprising a housing ( 5 ) with a receptacle ( 2 ) for the product, a dosing mechanism for setting a product dosage to be administered and for displaying the set product dosage, the dosing mechanism comprising a dosing sleeve ( 50 ) which is rotatable relative to the housing ( 5 ) in a first direction for setting a product dosage and which is rotatable relative to the housing ( 5 ) in a second, opposite direction for correcting or dispensing a product dosage, and a dispensing mechanism for dispensing the product, the dispensing mechanism comprising a piston rod ( 8 ), which is moveable relative to the housing ( 5 ) in a dispensing direction in order to eject the set product dosage in a dispensing stroke corresponding to the set product dosage, at least one sleeve ( 7 ; 40 ), which is rotatable together with the dosing sleeve ( 50 ) relative to the housing ( 5 ) in the second direction in
- the clutch ( 60 ) comprises first ratchet teeth ( 61 ) for engaging corresponding first teeth ( 51 ) of the dosing sleeve ( 50 ) such that relative incremental rotation of the dosing sleeve ( 50 ) with respect to the clutch ( 60 ) in one direction, preferably the first direction, is permitted while prevented in the opposite direction and second ratchet teeth ( 62 ) for engaging corresponding second teeth ( 41 ) of the at least one sleeve ( 7 ; 40 ) such that relative incremental rotation of the clutch ( 60 ) with respect to the at least one sleeve ( 7 ; 40 ) in one direction, preferably the second direction, is permitted while prevented in the opposite direction.
- first ratchet teeth ( 61 ) for engaging corresponding first teeth ( 51 ) of the dosing sleeve ( 50 ) such that relative incremental rotation of the dosing sleeve ( 50 ) with respect to the clutch ( 60 ) in one direction, preferably the first direction, is permitted
- the first detector ( 21 ) and/or a further detector are adapted to detect the relative incremental rotation between the clutch ( 60 ) and the dosing sleeve ( 50 ) and/or the housing ( 5 ) and/or the at least one sleeve ( 7 ; 40 ) in the first direction and/or to detect the relative incremental rotation between the clutch ( 60 ) and the dosing sleeve ( 50 ) and/or the housing ( 5 ) and/or the at least one sleeve ( 7 ; 40 ) in the second direction.
- the first ratchet teeth ( 61 ) and/or the second ratchet teeth ( 62 ) are coated with a galvanic conductive material and at least one of the first teeth ( 51 ) and/or at least one of the second teeth ( 41 ) are provided with an elastic galvanic contact arranged for engaging with the galvanic conductive material at each rotational increment, wherein the first detector ( 21 ) comprises the elastic galvanic contact and the galvanic conductive material.
- the first detector ( 21 ) comprises at least one mechanical switch which is provided between the first ratchet teeth ( 61 ) and the first teeth ( 51 ) and/or between the second ratchet teeth ( 62 ) and the second teeth ( 41 ) and is arranged for detecting engaging of the teeth ( 51 , 61 ; 41 , 62 ) at each rotational increment.
Abstract
Description
- The present application is the national stage entry of International Patent Application No. PCT/EP2019/057392, filed on Mar. 25, 2019, and claims priority to Application No. EP 18305345.3, filed on Mar. 28, 2018, the disclosures of which are incorporated herein by reference.
- The present disclosure is generally directed to an injection device, i.e. a drug delivery device for selecting and dispensing a number of user-variable doses of a medicament.
- Pen type drug delivery devices have application where regular injection by persons without formal medical training occurs. This may be increasingly common among patients having diabetes where self-treatment enables such patients to conduct effective management of their disease. In practice, such a drug delivery device allows a user to individually select and dispense a number of user-variable doses of a medicament. The present disclosure is not directed to so called fixed dose devices which only allow dispensing of a predefined dose without the possibility to increase or decrease the set dose.
- There are basically two types of drug delivery devices: resettable devices (i.e., reusable) and non-resettable (i.e., disposable). For example, disposable pen delivery devices are supplied as self-contained devices. Such self-contained devices do not have removable pre-filled cartridges. Rather, the pre-filled cartridges may not be removed and replaced from these devices without destroying the device itself. Consequently, such disposable devices need not have a resettable dose setting mechanism. The present disclosure is applicable for both types of devices, i.e. for disposable devices as well as for reusable devices.
- These types of pen delivery devices (so named because they often resemble an enlarged fountain pen) generally comprise three primary elements: a cartridge section that includes a cartridge often contained within a housing or holder; a needle assembly connected to one end of the cartridge section; and a dosing section connected to the other end of the cartridge section. A cartridge (often referred to as an ampoule) typically includes a reservoir that is filled with a medication (e.g., insulin), a movable rubber type bung or stopper located at one end of the cartridge reservoir, and a top having a pierceable rubber seal located at the other, often necked-down, end. A crimped annular metal band is typically used to hold the rubber seal in place. While the cartridge housing may be typically made of plastic, cartridge reservoirs have historically been made of glass.
- The needle assembly is typically a replaceable double-ended needle assembly. Before an injection, a replaceable double-ended needle assembly is attached to one end of the cartridge assembly, a dose is set, and then the set dose is administered. Such removable needle assemblies may be threaded onto, or pushed (i.e., snapped) onto the pierceable seal end of the cartridge assembly.
- The dosing section or dose setting mechanism is typically the portion of the pen device that is used to set (select) a dose. During an injection, a spindle or piston rod contained within the dose setting mechanism presses against the bung or stopper of the cartridge. This force causes the medication contained within the cartridge to be injected through an attached needle assembly. After an injection, as generally recommended by most drug delivery device and/or needle assembly manufacturers and suppliers, the needle assembly is removed and discarded.
- A further differentiation of drug delivery device types refers to the drive mechanism: There are devices which are manually driven, e.g. by a user applying a force to an injection button, devices which are driven by a spring or the like and devices which combine these two concepts, i.e. spring assisted devices which still require a user to exert an injection force. The spring-type devices involve springs which are preloaded and springs which are loaded by the user during dose selecting. Some stored-energy devices use a combination of spring preload and additional energy provided by the user, for example during dose setting.
- An injection device comprising a housing with a receptacle for the product, a dosing mechanism for setting a product dosage to be administered and for displaying the set product dosage and a dispensing mechanism for dispensing the product is known e.g. from
EP 2 814 547 B1 which discloses a manually driven device or from WO 2014/117944 A1, WO 2016/016184 A1 or WO 2017/134131 A1 which disclose spring driven devices. - These known devices are provided with a display providing a visual feedback to a user regarding the actually set dose size. The display of such devices typically involves a number sleeve with a series of numbers corresponding to dose sizes being provided on the outer surface of the number sleeve such that only the actually set dose is visible through an opening or window in the housing. Especially for visually impaired users, it may be desirable to get such information in a different manner, for example on a separate display unit and/or such that the information may be stored.
- It is an object of the present disclosure to provide an improved alternative to the above solutions. Especially, it is an object of the present disclosure to provide an injection device or a drug delivery device providing information to users regarding the set dose size.
- This object is solved by an injection device according to
claim 1. - An injection device according to the present disclosure comprises a housing with a receptacle for the product, a dosing mechanism for setting a product dosage to be administered and for displaying the set product dosage and a dispensing mechanism for dispensing the product. The dosing mechanism may comprise a dosing sleeve, e.g. a number sleeve with numbers or symbols provided on its outer surface, which is rotatable relative to the housing in a first direction for setting a product dosage and which is rotatable relative to the housing in a second, opposite direction for correcting or dispensing a product dosage. The dispensing mechanism of the device may comprise a piston rod, which is moveable relative to the housing in a dispensing direction in order to eject the set product dosage in a dispensing stroke corresponding to the set product dosage, at least one sleeve, which is rotatable together with the dosing sleeve relative to the housing in the second direction in order to eject the set product dosage, and a clutch interposed between the dosing sleeve and the at least one sleeve and rotatable with the dosing sleeve and/or the at least one sleeve. The present disclosure is based on the idea that detecting movements of one or more component parts of the injection device may be used to identify e.g. the actually set dose size and/or the actual operation mode of the device. If a relative rotation between the clutch and further component parts of the device occurs, e.g. in increments corresponding to dose units, this relative rotation may be used to identify the actually set dose size. For example, the device may further comprise at least a first detector for detecting movement of the clutch relative to the dosing sleeve and/or the housing and/or the at least one sleeve and a data processing unit connected to the first detector for reading, storing, processing, transmitting and/or displaying signals received from the first detector.
- In an exemplary embodiment, the clutch may comprise first ratchet teeth for engaging corresponding first teeth of the dosing sleeve such that relative incremental rotation of the dosing sleeve with respect to the clutch in one direction, preferably the first direction, is permitted while prevented in the opposite direction and second ratchet teeth for engaging corresponding second teeth of the at least one sleeve such that relative incremental rotation of the clutch with respect to the at least one sleeve in one direction, preferably the second direction, is permitted while prevented in the opposite direction. For example, the teeth may have the form of saw-teeth. The clutch may have the form of a toothed ring, like the toothed ring provided interposed between the dosing sleeve and the coupling sleeve in
EP 2 814 547 B1. Preferably, the first ratchet teeth and the second ratchet teeth are located on the clutch facing in opposite axial directions. The incremental or stepwise rotation may cause a clicking sound every time a pair of teeth re-engages thereby providing an acoustical and/or tactile feedback to the user. Typically, one click corresponds to one dose unit such that counting the number of clicks enables a user to identify the set dose size. - The present disclosure is suitable for devices permitting dose setting and dispensing the set dose as well as devices permitting dose setting, dose correcting and dispensing the set dose. In this respect dose correcting is defined as reducing the size of a set dose without dispensing the set dose. In other words, the term dose setting is used indicating increasing the set dose, while the term dose correcting is used indicating decreasing the set dose. Dose setting and dose correcting may include relative movement of the first and/or second ratchet teeth. Thus, detecting the clicks produced during dose setting and during dose correcting may be used to identify the resulting dose size.
- The first detector and the data processing unit are preferably adapted to detect at least one of a rotational movement of the clutch, an angle of rotation the rotational movement of the stop wheel and a direction of the rotational movement of the stop wheel. Detecting start and stop of the rotational movement is indicative of the device being used or not. Further, the angle of rotation is indicative of the size of a dose which is selected and/or dispensed by the drug delivery device. The direction of the rotational movement is indicative of the operation mode of the device, for example if the clutch rotates in a first direction during dose setting and rotates in a second, opposite direction during dose correction and/or dose dispensing. Summarizing, detecting the movement of the clutch provides the required information for giving a feedback to the user regarding the operation mode of the device. Further, the data processing unit may be adapted to provide information about the dose size and/or amount of product ejected from the device by the dispensing mechanism and/or the maximum dose set by the dosing mechanism based on a rotation protocol containing data received from the first detector. Either the first detector and/or a further detector are adapted to detect the relative incremental rotation between the clutch and any further component part of the device, e.g. the dosing sleeve and/or the housing and/or the at least one sleeve, in the first direction and/or in the second direction.
- As mentioned above, the relative incremental rotation between the clutch and the dosing sleeve and/or the at least one sleeve may generate an acoustic feedback to a user.
- Optionally, the first detector comprises at least one sensor for detecting this acoustic feedback generated by relative incremental rotation between the clutch and the dosing sleeve and/or the at least one sleeve. The sound generated during dose setting may differ from the sound generated during dose correcting such that the sensor may differentiate between dose setting and dose correcting. Other features may be used in conjunction or as an alternative to identify whether a dose is set or corrected, e.g. detecting the direction of rotation of the clutch and/or other component parts.
- As an alternative or in addition to detecting an acoustical feedback, the first ratchet teeth and/or the second ratchet teeth may be coated with a galvanic conductive material and at least one of the first teeth and/or at least one of the second teeth are provided with an elastic galvanic contact arranged for engaging with the galvanic conductive material at each rotational increment. In other words, the first detector comprises the elastic galvanic contact and the galvanic conductive material and each incremental rotational movement provides an electric signal which may be counted by the data processing unit. The resulting dose is e.g. calculated in counting the signals at the dialing end, e.g. the interface between the dose sleeve and the clutch, and subtracting the counted signals of the correcting end, e.g. the interface between the clutch and the at least one sleeve.
- According to a further embodiment, the first detector comprises at least one mechanical switch which is provided between the first ratchet teeth and the first teeth and/or between the second ratchet teeth and the second teeth and is arranged for detecting engaging of the teeth at each rotational increment. Each switch engages with the respective ratchet teeth at each incremental rotation and thus produces an electrical signal. The dose calculation is done in a similar manner by the data processing unit as mentioned above.
- In a further embodiment, the first detector comprises at least one of a magnetic sensor and an inductive sensor, e.g. suitable to detect the rotational position of the dosing sleeve and/or the clutch. Data received from such a sensor may be analyzed by an add-on device attached e.g. to a button or to the dosing sleeve. This method may be used to calculate the set dose size taking into account a possible dose correction. In other words, it is possible to detect the chosen dose by analyzing the rotational positions of the dosing sleeve and the clutch.
- The injection device may further comprise a second detector for detecting the relative axial position of the clutch and the dosing sleeve. The data processing unit may be connected to the second detector for reading, storing, processing, transmitting and/or displaying signals received from the second detector. The additional detector may be required to differentiate between dose setting, dose correcting and/or dose dispensing be determining the relative axial position of the dosing sleeve relative to the clutch. For example, the second detector comprises at least one of a magnetic sensor and an inductive sensor.
- Using a magnetic sensor or an inductive sensor may require that the clutch and/or the dosing sleeve comprise a metallic material. For example, the dosing sleeve and/or the clutch may be metallized, coated, printed or additives may be added to the component parts, which typically mainly comprise a plastic material.
- The data processing unit may be adapted to provide information about the device being in its dose setting mode, its dose correction mode or its dose dispensing mode based on data received from the first detector and the second detector. The data processing unit may be provided within the housing of the injection device. For example, the data processing unit and the first and second detector may be permanently provided within the housing of the injection device. This includes embodiments in which the data processing unit is connected to at least one of the first and second detector by wire. As an alternative, the data processing unit may be detachable from the housing and/or may be connected to at least one of the first and second detector by means of a wireless connection. In other words, the data processing unit may be an add-on device which may be attached to the housing and removed from the housing. Examples for wireless communication between the data processing unit and at least one detector may include communication via a near field communication (NFC) or via Bluetooth (BT).
- Further, the data processing unit may be adapted to send data to and/or receive data from a separate data processing and/or display device, e.g. portable handheld electronic devices, via a near field communication (NFC) or via Bluetooth (BT). The data may be queried after each use (injection) and read out or an add-on device could read, process and store the data and send a rotation protocol via to another device for further processing. The add-on device may alternatively transmit unprocessed data.
- The at least one sleeve may be a component part which is in direct engagement with the piston rod. For example, the at least one sleeve may be a drive sleeve which is splined to the piston rod or which is in threaded engagement with the piston rod. However, as an alternative, the at least one sleeve may be a component part which is indirectly coupled to the piston rod, for example with a clutch or a transmission element interposed between the at least one sleeve and the piston rod. The at least one sleeve may be permanently coupled to the piston rod or may be selectively coupled to the piston rod only in a certain mode of the injection device, for example during dose dispensing. The injection device may comprise two sleeves, which are rotatable relative to the housing in order to eject the set product dosage and which are rotationally constrained relative to each other but displaceable relative to each other in the dispensing direction. The second detector may detect actuation, i.e. rotation, of one of these sleeves or of both sleeves.
- The injection device typically comprises a cartridge containing a medicament. The term “medicament”, as used herein, means a pharmaceutical formulation containing at least one pharmaceutically active compound,
- wherein in one embodiment the pharmaceutically active compound has a molecular weight up to 1500 Da and/or is a peptide, a protein, a polysaccharide, a vaccine, a DNA, a RNA, an enzyme, an antibody or a fragment thereof, a hormone or an oligonucleotide, or a mixture of the above-mentioned pharmaceutically active compound,
- wherein in a further embodiment the pharmaceutically active compound is useful for the treatment and/or prophylaxis of diabetes mellitus or complications associated with diabetes mellitus such as diabetic retinopathy, thromboembolism disorders such as deep vein or pulmonary thromboembolism, acute coronary syndrome (ACS), angina, myocardial infarction, cancer, macular degeneration, inflammation, hay fever, atherosclerosis and/or rheumatoid arthritis,
- wherein in a further embodiment the pharmaceutically active compound comprises at least one peptide for the treatment and/or prophylaxis of diabetes mellitus or complications associated with diabetes mellitus such as diabetic retinopathy,
- wherein in a further embodiment the pharmaceutically active compound comprises at least one human insulin or a human insulin analogue or derivative, glucagon-like peptide (GLP-1) or an analogue or derivative thereof, or exendin-3 or exendin-4 or an analogue or derivative of exendin-3 or exendin-4.
- Insulin analogues are for example Gly(A21), Arg(B31), Arg(B32) human insulin; Lys(B3), Glu(B29) human insulin; Lys(B28), Pro(B29) human insulin; Asp(B28) human insulin; human insulin, wherein proline in position B28 is replaced by Asp, Lys, Leu, Val or Ala and wherein in position B29 Lys may be replaced by Pro; Ala(B26) human insulin; Des(B28-B30) human insulin; Des(B27) human insulin and Des(B30) human insulin.
- Insulin derivates are for example B29-N-myristoyl-des(B30) human insulin; B29-N-palmitoyl-des(B30) human insulin; B29-N-myristoyl human insulin; B29-N-palmitoyl human insulin; B28-N-myristoyl LysB28ProB29 human insulin; B28-N-palmitoyl-LysB28ProB29 human insulin; B30-N-myristoyl-ThrB29LysB30 human insulin; B30-N-palmitoyl-ThrB29LysB30 human insulin; B29-N—(N-palmitoyl-Y-glutamyl)-des(B30) human insulin; B29-N—(N-lithocholyl-Y-glutamyl)-des(B30) human insulin; B29-N-(ω-carboxyheptadecanoyl)-des(B30) human insulin and B29-N-(ω-carboxyheptadecanoyl) human insulin.
- Exendin-4 for example means Exendin-4(1-39), a peptide of the sequence H-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2.
- Exendin-4 derivatives are for example selected from the following list of compounds:
- H-(Lys)4-des Pro36, des Pro37 Exendin-4(1-39)-NH2,
- H-(Lys)5-des Pro36, des Pro37 Exendin-4(1-39)-NH2,
- des Pro36 Exendin-4(1-39),
- des Pro36 [Asp28] Exendin-4(1-39),
- des Pro36 [IsoAsp28] Exendin-4(1-39),
- des Pro36 [Met(O)14, Asp28] Exendin-4(1-39),
- des Pro36 [Met(O)14, IsoAsp28] Exendin-4(1-39),
- des Pro36 [Trp(O2)25, Asp28] Exendin-4(1-39),
- des Pro36 [Trp(O2)25, IsoAsp28] Exendin-4(1-39),
- des Pro36 [Met(O)14 Trp(O2)25, Asp28] Exendin-4(1-39),
- des Pro36 [Met(O)14 Trp(O2)25, IsoAsp28] Exendin-4(1-39); or
- des Pro36 [Asp28] Exendin-4(1-39),
- des Pro36 [IsoAsp28] Exendin-4(1-39),
- des Pro36 [Met(O)14, Asp28] Exendin-4(1-39),
- des Pro36 [Met(O)14, IsoAsp28] Exendin-4(1-39),
- des Pro36 [Trp(O2)25, Asp28] Exendin-4(1-39),
- des Pro36 [Trp(O2)25, IsoAsp28] Exendin-4(1-39),
- des Pro36 [Met(O)14 Trp(O2)25, Asp28] Exendin-4(1-39),
- des Pro36 [Met(O)14 Trp(O2)25, IsoAsp28] Exendin-4(1-39),
- wherein the group -Lys6-NH2 may be bound to the C-terminus of the Exendin-4 derivative;
- or an Exendin-4 derivative of the sequence
- des Pro36 Exendin-4(1-39)-Lys6-NH2 (AVE0010),
- H-(Lys)6-des Pro36 [Asp28] Exendin-4(1-39)-Lys6-NH2,
- des Asp28 Pro36, Pro37, Pro38Exendin-4(1-39)-NH2,
- H-(Lys)6-des Pro36, Pro38 [Asp28] Exendin-4(1-39)-NH2,
- H-Asn-(Glu)5des Pro36, Pro37, Pro38 [Asp28] Exendin-4(1-39)-NH2,
- des Pro36, Pro37, Pro38 [Asp28] Exendin-4(1-39)-(Lys)6-NH2,
- H-(Lys)6-des Pro36, Pro37, Pro38 [Asp28] Exendin-4(1-39)-(Lys)6-NH2,
- H-Asn-(Glu)5-des Pro36, Pro37, Pro38 [Asp28] Exendin-4(1-39)-(Lys)6-NH2,
- H-(Lys)6-des Pro36 [Trp(O2)25, Asp28] Exendin-4(1-39)-Lys6-NH2,
- H-des Asp28 Pro36, Pro37, Pro38 [Trp(O2)25] Exendin-4(1-39)-NH2,
- H-(Lys)6-des Pro36, Pro37, Pro38 [Trp(O2)25, Asp28] Exendin-4(1-39)-NH2,
- H-Asn-(Glu)5-des Pro36, Pro37, Pro38 [Trp(O2)25, Asp28] Exendin-4(1-39)-NH2,
- des Pro36, Pro37, Pro38 [Trp(O2)25, Asp28] Exendin-4(1-39)-(Lys)6-NH2,
- H-(Lys)6-des Pro36, Pro37, Pro38 [Trp(O2)25, Asp28] Exendin-4(1-39)-(Lys)6-NH2,
- H-Asn-(Glu)5-des Pro36, Pro37, Pro38 [Trp(O2)25, Asp28] Exendin-4(1-39)-(Lys)6-NH2,
- H-(Lys)6-des Pro36 [Met(O)14, Asp28] Exendin-4(1-39)-Lys6-NH2,
- des Met(O)14 Asp28 Pro36, Pro37, Pro38 Exendin-4(1-39)-NH2,
- H-(Lys)6-desPro36, Pro37, Pro38 [Met(O)14, Asp28] Exendin-4(1-39)-NH2,
- H-Asn-(Glu)5-des Pro36, Pro37, Pro38 [Met(O)14, Asp28] Exendin-4(1-39)-NH2,
- des Pro36, Pro37, Pro38 [Met(O)14, Asp28] Exendin-4(1-39)-(Lys)6-NH2,
- H-(Lys)6-des Pro36, Pro37, Pro38 [Met(O)14, Asp28] Exendin-4(1-39)-(Lys)6-NH2,
- H-Asn-(Glu)5 des Pro36, Pro37, Pro38 [Met(O)14, Asp28] Exendin-4(1-39)-(Lys)6-NH2,
- H-Lys6-des Pro36 [Met(O)14, Trp(O2)25, Asp28] Exendin-4(1-39)-Lys6-NH2,
- H-des Asp28 Pro36, Pro37, Pro38 [Met(O)14, Trp(O2)25] Exendin-4(1-39)-NH2,
- H-(Lys)6-des Pro36, Pro37, Pro38 [Met(O)14, Asp28] Exendin-4(1-39)-NH2,
- H-Asn-(Glu)5-des Pro36, Pro37, Pro38 [Met(O)14, Trp(O2)25, Asp28] Exendin-4(1-39)-NH2,
- des Pro36, Pro37, Pro38 [Met(O)14, Trp(O2)25, Asp28] Exendin-4(1-39)-(Lys)6-NH2,
- H-(Lys)6-des Pro36, Pro37, Pro38 [Met(O)14, Trp(O2)25, Asp28] Exendin-4(S1-39)-(Lys)6-NH2,
- H-Asn-(Glu)5-des Pro36, Pro37, Pro38 [Met(O)14, Trp(O2)25, Asp28] Exendin-4(1-39)-(Lys)6-NH2;
- or a pharmaceutically acceptable salt or solvate of any one of the afore-mentioned Exendin-4 derivative.
- Hormones are for example hypophysis hormones or hypothalamus hormones or regulatory active peptides and their antagonists as listed in Rote Liste, ed. 2008,
Chapter 50, such as Gonadotropine (Follitropin, Lutropin, Choriongonadotropin, Menotropin), Somatropine (Somatropin), Desmopressin, Terlipressin, Gonadorelin, Triptorelin, Leuprorelin, Buserelin, Nafarelin, Goserelin. - A polysaccharide is for example a glucosaminoglycane, a hyaluronic acid, a heparin, a low molecular weight heparin or an ultra low molecular weight heparin or a derivative thereof, or a sulphated, e.g. a poly-sulphated form of the above-mentioned polysaccharides, and/or a pharmaceutically acceptable salt thereof. An example of a pharmaceutically acceptable salt of a poly-sulphated low molecular weight heparin is enoxaparin sodium.
- Antibodies are globular plasma proteins (˜150 kDa) that are also known as immunoglobulins which share a basic structure. As they have sugar chains added to amino acid residues, they are glycoproteins. The basic functional unit of each antibody is an immunoglobulin (Ig) monomer (containing only one Ig unit); secreted antibodies can also be dimeric with two Ig units as with IgA, tetrameric with four Ig units like teleost fish IgM, or pentameric with five Ig units, like mammalian IgM.
- The Ig monomer is a “Y”-shaped molecule that consists of four polypeptide chains; two identical heavy chains and two identical light chains connected by disulfide bonds between cysteine residues. Each heavy chain is about 440 amino acids long; each light chain is about 220 amino acids long. Heavy and light chains each contain intrachain disulfide bonds which stabilize their folding. Each chain is composed of structural domains called Ig domains. These domains contain about 70-110 amino acids and are classified into different categories (for example, variable or V, and constant or C) according to their size and function. They have a characteristic immunoglobulin fold in which two β sheets create a “sandwich” shape, held together by interactions between conserved cysteines and other charged amino acids.
- There are five types of mammalian Ig heavy chain denoted by α, δ, ε, γ, and μ. The type of heavy chain present defines the isotype of antibody; these chains are found in IgA, IgD, IgE, IgG, and IgM antibodies, respectively.
- Distinct heavy chains differ in size and composition; α and γ contain approximately 450 amino acids and δ approximately 500 amino acids, while μ and ε have approximately 550 amino acids. Each heavy chain has two regions, the constant region (CH) and the variable region (VH). In one species, the constant region is essentially identical in all antibodies of the same isotype, but differs in antibodies of different isotypes. Heavy chains γ, α and δ have a constant region composed of three tandem Ig domains, and a hinge region for added flexibility; heavy chains μ and ε have a constant region composed of four immunoglobulin domains. The variable region of the heavy chain differs in antibodies produced by different B cells, but is the same for all antibodies produced by a single B cell or B cell clone. The variable region of each heavy chain is approximately 110 amino acids long and is composed of a single Ig domain.
- In mammals, there are two types of immunoglobulin light chain denoted by λ and κ. A light chain has two successive domains: one constant domain (CL) and one variable domain (VL). The approximate length of a light chain is 211 to 217 amino acids. Each antibody contains two light chains that are always identical; only one type of light chain, κ or λ, is present per antibody in mammals.
- Although the general structure of all antibodies is very similar, the unique property of a given antibody is determined by the variable (V) regions, as detailed above. More specifically, variable loops, three each the light (VL) and three on the heavy (VH) chain, are responsible for binding to the antigen, i.e. for its antigen specificity. These loops are referred to as the Complementarity Determining Regions (CDRs). Because CDRs from both VH and VL domains contribute to the antigen-binding site, it is the combination of the heavy and the light chains, and not either alone, that determines the final antigen specificity.
- An “antibody fragment” contains at least one antigen binding fragment as defined above, and exhibits essentially the same function and specificity as the complete antibody of which the fragment is derived from. Limited proteolytic digestion with papain cleaves the Ig prototype into three fragments. Two identical amino terminal fragments, each containing one entire L chain and about half an H chain, are the antigen binding fragments (Fab). The third fragment, similar in size but containing the carboxyl terminal half of both heavy chains with their interchain disulfide bond, is the crystalizable fragment (Fc). The Fc contains carbohydrates, complement-binding, and FcR-binding sites. Limited pepsin digestion yields a single F(ab′)2 fragment containing both Fab pieces and the hinge region, including the H—H interchain disulfide bond. F(ab′)2 is divalent for antigen binding. The disulfide bond of F(ab′)2 may be cleaved in order to obtain Fab′. Moreover, the variable regions of the heavy and light chains can be fused together to form a single chain variable fragment (scFv).
- Pharmaceutically acceptable salts are for example acid addition salts and basic salts. Acid addition salts are e.g. HCl or HBr salts. Basic salts are e.g. salts having a cation selected from alkali or alkaline, e.g. Na+, or K+, or Ca2+, or an ammonium ion N+(R1)(R2)(R3)(R4), wherein R1 to R4 independently of each other mean: hydrogen, an optionally substituted C1-C6-alkyl group, an optionally substituted C2-C6-alkenyl group, an optionally substituted C6-C10-aryl group, or an optionally substituted C6-C10-heteroaryl group. Further examples of pharmaceutically acceptable salts are described in “Remington's Pharmaceutical Sciences” 17. ed. Alfonso R. Gennaro (Ed.), Mark Publishing Company, Easton, Pa., U.S.A., 1985 and in Encyclopedia of Pharmaceutical Technology.
- Pharmaceutically acceptable solvates are for example hydrates.
- Non-limiting, exemplary embodiments of the disclosure will now be described with reference to the accompanying drawings, in which:
-
FIG. 1 shows an exploded view of the individual parts of an embodiment of an injection device according to the disclosure; -
FIG. 2 shows a sectional view of a detail of the embodiment ofFIG. 1 ; -
FIGS. 3a-3c show component parts of the injection device ofFIG. 1 ; and -
FIG. 4 schematically shows a data processing unit together with sensors. -
FIG. 1 shows an exploded view of the individual parts of an embodiment of an injection device according to the disclosure. This embodiment is designed as a so-called single-use pen. That is to say, the injection device is issued to the user fully assembled, i.e., with product to be administered. - The typical course of the injection process may be as follows: the user removes the
protective cap 1 from the injection device and mounts an injection needle (not shown) on theneedle holder 2 a of areceptacle 2. Now the dosage can be adjusted via therotary knob 11 a. For this purpose, therotary knob 11 a is turned so that thedosing sleeve 50, which forms a dosing mechanism or is part of a dosing mechanism, is screwed out of the injection device. - The
dosing sleeve 50 is screwed out of the injection device until the desired dosage is displayed in the window of the threadedsleeve 9. If an excessively high dosage is inadvertently set, the dosage can be corrected by turning the rotary knob in the opposite direction, whereby thedosing sleeve 50 is screwed back into the housing. The dosing device limits the maximum adjustable dosage to a predetermined value. If there is an attempt to screw the dosing sleeve out of the housing past this value, a radial limit stop on thedosing sleeve 50 and a counter-limit stop on the threadedsleeve 9 prevent further rotation by mutual interaction. During the dosing and correction movements, thedosing sleeve 50 rotates relative to thecoupling sleeve 40. Thecoupling sleeve 40 is held rotationally fixedly in a form fit or friction fit against thehousing 5 by a reverse rotation lock, for example by means of atoothed ring 7 a rotationally fixed to the threadednut 7 and biased axially towards a corresponding set of ratchet teeth on an inner surface of thehousing 5 by means of aspring 7 b. This ratchet between thehousing 5 and the threadednut 7 may form a clicker generating an audible and/or tactile feedback during dose dispensing as the teeth ofring 7 a slip over the corresponding teeth ofhousing 5. - The
coupling sleeve 40 is permanently rotationally locked to the axially stationary threadednut 7 by splines permitting relative axial movement between thecoupling sleeve 40 which is axially entrained by thedosing sleeve 50 and the stationary threadednut 7. The threadednut 7 may be retained in thehousing 5 by means of aninsert 6 holding the threadednut 7 against the bias ofspring 7 b. A clutch 60 is shown inFIG. 1 as a toothed ring which is interposed betweenrotary knob 11 a and a flange on couplingsleeve 40 such that relative rotation of thedosing sleeve 50 and thecoupling sleeve 40 is permitted during dose setting.FIGS. 2, 3 a, 3 b and 3 c show in detail that the clutch is provided withfirst ratchet teeth 61 on an end facing towards correspondingfirst teeth 51 of thedosing sleeve 50 and is provided withsecond ratchet teeth 62 on an opposite end facing towards correspondingsecond teeth 41 of thecoupling sleeve 40. - The
ratchet teeth interface dosing sleeve 50 and the clutch 60 is designed such that rotation of thedosing sleeve 50 in a first direction, e.g. during dose setting, is permitted relative to the stationary clutch 60 withteeth teeth dosing sleeve 50 and the clutch 60 in the opposite direction is prevented. Theratchet teeth interface coupling sleeve 40 and the clutch 60 is designed such that rotation of the clutch 60 in a second direction, e.g. during dose correcting, is permitted relative to thestationary coupling sleeve 40 withteeth teeth coupling sleeve 40 and the clutch 60 in the opposite direction is prevented.Spring 13 keeps the ratchet interfaces 51, 61 and 41, 62 in contact but allows axial displacement of the clutch 60 and/or thecoupling sleeve 40 against the bias ofspring 13 to allow slipping of the interfaces as described above. - In the embodiments depicted in the Figures,
multiple teeth first ratchet teeth 61 at least onetooth 51 would be provided on thedosing sleeve 50 and vice versa. In the same way, multiplesecond ratchet teeth 62 may interact with at least onetooth 41 and vice versa. While the torque transmitted by an interface having multiple engaging teeth may be increased compared with only a single pair of teeth engaging, providing only one or only few teeth on one of the component parts may have advantages when providing a sensor in or on this component part. - If the desired dosage has been set, the injection needle can be inserted at the intended position on the body of the user. Then the user pushes the
ejection button 14 in the distal axial direction against the bias ofspring 13 which is interposed betweenbutton 14 andcoupling sleeve 40. This axial movement blocks a relative rotation between thecoupling sleeve 40 and thedosing sleeve 50 by means of the toothed ring of clutch 60, i.e. thecoupling sleeve 40 and thedosing sleeve 50 are rotationally constrained via the clutch 60. In case of further pressure in the distal axial direction, the dosing sleeve begins to move back into the housing in a screwing motion. Because of the established rotational lock between thedosing sleeve 50 and thecoupling sleeve 40, thecoupling sleeve 40 carries out the same movement as thedosing sleeve 50. Because thecoupling sleeve 40 is permanently rotationally locked to the axially stationary threadednut 7, the rotational movement of thedosing sleeve 50 is transmitted to the threadednut 7. No axial forces are transmitted to the threadednut 7, because thecoupling sleeve 40 is mounted axially movably on the threadednut 7. Thus, the rotating threadednut 7 produces an axial movement of the threadedpiston rod 8 in the distal direction, wherein the latter is guided axially and locked rotationally in thehousing 5 by means ofsplines 8 a and is in threaded engagement with threadednut 7 by means of an external thread 8 g. Theflange 4 acts on the plug of thecartridge 3 and pushes it, corresponding to the displacement of the threadedpiston rod 8 in the distal direction as well, wherein the previously set dosage can be ejected or administered. At the end of the administration, when the dosing sleeve has been completely screwed back into the housing, radial stops on thedosing sleeve 50 and the threadedsleeve 9 prevent further ejection and overrotation of the dosing device. - The embodiment of
FIG. 1 shows an optional limiting device which ensures that the most recently set dosage can be completely ejected or injected. For this purpose, thedosing sleeve 50 has a coaxially applied inner toothing and thecoupling sleeve 40 has a lateral cutout in which thestop wheel 30 is inserted. The function of the limiting device is described inEP 2 814 547 B1 in more detail. - The embodiment of
FIG. 1 further shows adata processing unit 20 connected to afirst detector 21 and asecond detector 22 for reading data responsive to signals received from the first andsecond detectors data processing unit 20 is depicted as a component part being disposed on the outer surface of thehousing 5. It may be permanently attached to thehousing 5 or may be an integral part thereof or may be a separate, detachable unit. Thedata processing unit 20 may comprise a power supply and a PCB suitable for e.g. data processing, data storing and/or display of information. - The
first detector 21 is disposed on the clutch 60. In more detail thefirst detector 21 may comprise a coating on theratchet teeth ratchet teeth first teeth 51 and/orsecond teeth 41 to engage with the galvanic conductive material. Thus, every time theteeth - Instead of the
first detector 21 being provided at least partially on the clutch 60, thefirst detector 21 may be provided on thedosing sleeve 50. For example, thefirst detector 21 may be a magnetic rotation encoder (quadrature), a vibrating structure microelectromechanical systems (MEMS) gyroscope or a combination of an MEMS gyroscope and an accelerometer. These small size devices may be easibily integrated into thedosing sleeve 50. Generally, gyroscopes measure rotational motion. MEMS (microelectromechanical system) gyroscopes are small, inexpensive sensors that measure angular velocity. The units of angular velocity are measured in degrees per second (°/s) or revolutions per second (RPS). Hence, when determining the duration of the measurement the rotation angle can be determined that provides information about the dose size. - The optional
second detector 22 is disposed in or on thehousing 5 at a position suitable for detecting axial movement of the clutch 60. As the clutch 60 is axially entrained when thedosing sleeve 50 moves axially with respect to thehousing 5 thesecond detector 22 may be arranged on thedosing sleeve 50. If thefirst detector 21 is provided on thedosing sleeve 50, the first andsecond detectors -
FIG. 4 shows thefirst detector 21 with twosensors data processing unit 20. The processing of the signals from the sensors in thedata processing unit 20 is schematically indicated inFIG. 4 . - The feature of a
data processing unit 20 using the signals of afirst detector 21 and, optionally, asecond detector 22 for counting the size of the set dose may be applied to other drug delivery devices having a component part, like a sleeve, wheel or ring, performing a certain axial and/or rotational movement only during dose setting and a different movement during dose correcting. Examples for devices into which thedata processing unit 20 with thefirst detector 21 and thesecond detector 22 may be implemented are disclosed in WO 2014/117944 A1, in WO 2016/016184 A1, in WO 2017/134131 A1 or in WO 2016/001304 A1. - An injection device according to an embodiment of the disclosure may be defined as follows:
- An injection device comprising a housing (5) with a receptacle (2) for the product, a dosing mechanism for setting a product dosage to be administered and for displaying the set product dosage, the dosing mechanism comprising a dosing sleeve (50) which is rotatable relative to the housing (5) in a first direction for setting a product dosage and which is rotatable relative to the housing (5) in a second, opposite direction for correcting or dispensing a product dosage, and a dispensing mechanism for dispensing the product, the dispensing mechanism comprising a piston rod (8), which is moveable relative to the housing (5) in a dispensing direction in order to eject the set product dosage in a dispensing stroke corresponding to the set product dosage, at least one sleeve (7; 40), which is rotatable together with the dosing sleeve (50) relative to the housing (5) in the second direction in order to eject the set product dosage, and a clutch (60) interposed between the dosing sleeve (50) and the at least one sleeve (7; 40) and rotatable with the dosing sleeve (50) and/or the at least one sleeve (7; 40), wherein the device further comprises at least a first detector (21) for detecting movement of the clutch (60) relative to the dosing sleeve (50) and/or the housing (5) and/or the at least one sleeve (7; 40) and a data processing unit (20) connected to the first detector (21) for reading, storing, processing, transmitting and/or displaying signals received from the first detector (21). Preferably, the clutch (60) comprises first ratchet teeth (61) for engaging corresponding first teeth (51) of the dosing sleeve (50) such that relative incremental rotation of the dosing sleeve (50) with respect to the clutch (60) in one direction, preferably the first direction, is permitted while prevented in the opposite direction and second ratchet teeth (62) for engaging corresponding second teeth (41) of the at least one sleeve (7; 40) such that relative incremental rotation of the clutch (60) with respect to the at least one sleeve (7; 40) in one direction, preferably the second direction, is permitted while prevented in the opposite direction. In an example, the first detector (21) and/or a further detector are adapted to detect the relative incremental rotation between the clutch (60) and the dosing sleeve (50) and/or the housing (5) and/or the at least one sleeve (7; 40) in the first direction and/or to detect the relative incremental rotation between the clutch (60) and the dosing sleeve (50) and/or the housing (5) and/or the at least one sleeve (7; 40) in the second direction.
- For example, in the injection device according to this embodiment the first ratchet teeth (61) and/or the second ratchet teeth (62) are coated with a galvanic conductive material and at least one of the first teeth (51) and/or at least one of the second teeth (41) are provided with an elastic galvanic contact arranged for engaging with the galvanic conductive material at each rotational increment, wherein the first detector (21) comprises the elastic galvanic contact and the galvanic conductive material. According to an alternative example, in the injection device according to this embodiment the first detector (21) comprises at least one mechanical switch which is provided between the first ratchet teeth (61) and the first teeth (51) and/or between the second ratchet teeth (62) and the second teeth (41) and is arranged for detecting engaging of the teeth (51, 61; 41, 62) at each rotational increment.
-
- 1 cap
- 2 receptacle
- 2 a needle holder
- 3 cartridge
- 4 flange
- 5 housing
- 6 insert
- 7 threaded nut
- 7 a toothed ring
- 7 b spring
- 8 piston rod
- 8 a spline
- 8 b thread
- 9 threaded sleeve
- 11 a rotary knob
- 13 spring
- 14 button
- 20 data processing unit
- 21 first detector
- 21 a sensor
- 21 b sensor
- 22 second detector
- 30 stop wheel
- 41 coupling sleeve
- 41 second teeth
- 50 dosing sleeve
- 51 first teeth
- 60 clutch
- 61 first ratchet teeth
- 62 second ratchet teeth
Claims (20)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18305345.3 | 2018-03-28 | ||
EP18305345.3A EP3545995A1 (en) | 2018-03-28 | 2018-03-28 | Injection device |
EP18305345 | 2018-03-28 | ||
PCT/EP2019/057392 WO2019185517A1 (en) | 2018-03-28 | 2019-03-25 | Injection device |
Publications (2)
Publication Number | Publication Date |
---|---|
US20210038821A1 true US20210038821A1 (en) | 2021-02-11 |
US11724039B2 US11724039B2 (en) | 2023-08-15 |
Family
ID=61965869
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/976,202 Active 2040-08-25 US11724039B2 (en) | 2018-03-28 | 2019-03-25 | Injection device |
Country Status (5)
Country | Link |
---|---|
US (1) | US11724039B2 (en) |
EP (2) | EP3545995A1 (en) |
JP (1) | JP7414727B2 (en) |
CN (1) | CN111886040B (en) |
WO (1) | WO2019185517A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111322291B (en) * | 2020-02-24 | 2021-06-29 | 苏州恒瑞宏远医疗科技有限公司 | Release feedback system of motion device |
CN111282094B (en) * | 2020-03-05 | 2020-11-10 | 苏州恒瑞宏远医疗科技有限公司 | Automatic injection device and method of use |
EP4122513A1 (en) * | 2021-07-22 | 2023-01-25 | Ypsomed AG | Improved actuating arrangement for a pen |
CN117138165B (en) * | 2023-10-27 | 2024-01-23 | 江苏万海医疗器械有限公司 | Prefabricated material pushing device, conveyor and use method |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3067081A1 (en) * | 2015-03-12 | 2016-09-14 | Sanofi | Drug delivery device |
US20180036484A1 (en) * | 2015-02-27 | 2018-02-08 | Novo Nordisk A/S | Accessory Device with Mounting Safety Feature |
US20180126088A1 (en) * | 2015-05-12 | 2018-05-10 | Novo Nordisk A/S | Rotary Sensor Arrangement for Drug Delivery Device |
US20190192782A1 (en) * | 2016-05-30 | 2019-06-27 | Novo Nordisk A/S | Mounting feature for accessory device |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2738880A1 (en) | 2008-11-06 | 2010-05-14 | Novo Nordisk A/S | Electronically assisted drug delivery device |
CH706567A2 (en) | 2012-05-16 | 2013-11-29 | Tecpharma Licensing Ag | Improved device to set a dose a limiting mechanism for an apparatus for administering a product. |
WO2014117944A1 (en) | 2013-02-01 | 2014-08-07 | Novo Nordisk A/S | A non-axial working end-of content mechanism and an injection device comprising the same |
CN105120924B (en) * | 2013-04-05 | 2019-05-28 | 诺和诺德股份有限公司 | Medicament delivery device with integrated magnetic movement indicator |
DK2983760T3 (en) * | 2013-04-10 | 2018-01-02 | Sanofi Sa | INJECTION DEVICE |
TW201611853A (en) * | 2014-07-01 | 2016-04-01 | Sanofi Sa | Injection device |
TW201603849A (en) | 2014-07-01 | 2016-02-01 | 賽諾菲公司 | Clicker arrangement and drug delivery herewith |
EP3180056A1 (en) | 2014-07-28 | 2017-06-21 | Novo Nordisk A/S | A stop mechanism for a hypocycloid end-of-content mechanism in an injection device |
US10384013B2 (en) * | 2014-10-03 | 2019-08-20 | Novo Nordisk A/S | Pen-type drug injector and add-on module with magnetic dosage sensor system and error detection |
EP3250264A1 (en) * | 2015-01-29 | 2017-12-06 | Sanofi | Trigger mechanism and drug delivery device herewith |
CN108601909A (en) | 2016-02-02 | 2018-09-28 | 诺和诺德股份有限公司 | Hypocycloid formula Content mechanism |
-
2018
- 2018-03-28 EP EP18305345.3A patent/EP3545995A1/en active Pending
-
2019
- 2019-03-25 WO PCT/EP2019/057392 patent/WO2019185517A1/en unknown
- 2019-03-25 JP JP2020551861A patent/JP7414727B2/en active Active
- 2019-03-25 EP EP19711624.7A patent/EP3773819A1/en active Pending
- 2019-03-25 US US16/976,202 patent/US11724039B2/en active Active
- 2019-03-25 CN CN201980021646.9A patent/CN111886040B/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20180036484A1 (en) * | 2015-02-27 | 2018-02-08 | Novo Nordisk A/S | Accessory Device with Mounting Safety Feature |
EP3067081A1 (en) * | 2015-03-12 | 2016-09-14 | Sanofi | Drug delivery device |
US20180126088A1 (en) * | 2015-05-12 | 2018-05-10 | Novo Nordisk A/S | Rotary Sensor Arrangement for Drug Delivery Device |
US20190192782A1 (en) * | 2016-05-30 | 2019-06-27 | Novo Nordisk A/S | Mounting feature for accessory device |
Also Published As
Publication number | Publication date |
---|---|
EP3773819A1 (en) | 2021-02-17 |
EP3545995A1 (en) | 2019-10-02 |
JP7414727B2 (en) | 2024-01-16 |
US11724039B2 (en) | 2023-08-15 |
CN111886040B (en) | 2023-04-04 |
JP2021519144A (en) | 2021-08-10 |
WO2019185517A1 (en) | 2019-10-03 |
CN111886040A (en) | 2020-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2814543B1 (en) | Pen-type drug injection device and electronic add-on monitoring module for monitoring and logging dose setting and administration | |
US11724039B2 (en) | Injection device | |
US10695503B2 (en) | Drive sleeve, drug delivery device and method for assembling a drug delivery device | |
US10350360B2 (en) | Drug injection device with resettable mechanism allowing piston rod retraction upon drug cartridge change | |
EP3256195A1 (en) | Drive mechanism for an injection device | |
EP3204067A1 (en) | Insert and drug delivery device herewith | |
AU2015329906B2 (en) | Dosing assembly for drug delivery device with different leads and multi-start thread section | |
EP3706835A1 (en) | Injection device with a dose limiter | |
US20210290856A1 (en) | Injection device | |
US20210113778A1 (en) | Injection Device | |
US20220241513A1 (en) | Injection Device with a Filling Level Indicator | |
EP3545996A1 (en) | Injection device with distance sensor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: SANOFI, FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BLANCKE, STEFAN;REEL/FRAME:057932/0609 Effective date: 20190525 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
CC | Certificate of correction |